Biofrontera Q3 revenue rises 30% on higher Ameluz sales
BFRI•Biofrontera's third-quarter revenue rose 30% year over year to $9.1 million, while its net loss was $6.4 million. The company said higher Ameluz sales drove growth and expects to prepare for commercialization of Ameluz for sBCC in late Q4 2026 and early Q1 2027.
1. Revenue and losses
Third-quarter revenue rose 30% year over year to $9.1 million. Biofrontera reported a net loss of $6.4 million and an adjusted EBITDA loss of $5.5 million, compared with $6.0 million a year earlier.
2. Ameluz sales drivers
The company said revenue growth was primarily driven by a 23.3% increase in Ameluz unit volume, with additional contributions from price and mix and device sales. It said some customers accelerated orders in anticipation of potential supply restrictions from an ITC exclusion order.
3. Regulatory and commercial plans
Biofrontera submitted a supplemental New Drug Application to expand Ameluz's label for actinic keratosis. It is preparing to commercialize Ameluz for sBCC in late Q4 2026 and early Q1 2027.
